Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-10-01
Disclosure Type: Major Management Matters Related to Investment Decisions
💡 3-Second Summary
Alteogen is set to receive a milestone payment of USD 25,000,000 (approx. KRW 35.05B) within 30 days, triggered by global pharmaceutical giant MSD successfully obtaining U.S. FDA marketing approval for Pembrolizumab SC, which incorporates Alteogen’s ALT-B4 technology.
📊 1. [Summary of Core Disclosure Content and Key Figures]
- Recipient and Amount: Alteogen is scheduled to receive USD 25,000,000 (KRW 35,055,000,000) under the technology export and license agreement for its proprietary human hyaluronidase technology (ALT-B4) with MSD International Business GmbH (MSD).
- Condition and Background: The milestone was achieved due to the U.S. FDA marketing authorization approval of ‘Pembrolizumab SC’ (subcutaneous formulation).
- Financial Scale: The milestone payment amount exceeds 10% of Alteogen’s consolidated revenue from the previous year (approx. KRW 102.85B).
- Foreign Exchange Rate Base: The applied standard foreign exchange rate is KRW 1,402.2/USD, based on the Seoul Foreign Forex Brokerage market average rate on September 30, 2025.
- Payment Timeline and Conditions: The payment is expected to be received within 30 days from the invoice issuance date (2025-09-30). Alteogen has no obligation to return the milestone payment even if the contract terminates due to any future unfulfilled trials or commercialization.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This disclosure provides decisive validation that Alteogen’s core ALT-B4 platform tech has successfully cleared the final regulatory hurdles of the U.S. FDA, the world’s largest pharmaceutical market. A non-refundable cash inflow equivalent to more than 34% of the previous year’s total annual consolidated revenue will be realized within 30 days, which could have a highly positive potential impact on the company’s short-term liquidity and financial metrics.
Crucially, as this milestone stems from the U.S. approval of a subcutaneous version of a global blockbuster immunotherapy, it should be interpreted as a milestone breakthrough that may trigger substantial long-term enhancements in the company’s business Fundamental, such as consecutive commercial royalties upon product rollout.
📝 Editor’s Comment (by K-STOCK Editor)
The most anticipated and highest-certainty event in a biotech firm’s lifecycle—a U.S. FDA approval milestone—has officially materialized. The partnership, which initially began under strict confidentiality clauses in 2020, was revealed as MSD’s Keytruda SC during the contract amendment in February 2024 and has now crossed the commercialization finish line in the U.S. The influx of roughly KRW 35.05B in non-refundable cash directly strengthens the company’s financial base. More importantly, this final clearance acts as an undeniable global endorsement of Alteogen’s SC formulation platform technology.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!